| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | hTAP; SEC14 like 2; Sec14l2; SPF; Squalene transfer protein; TAP; TAP1;;SEC14L2 |
| WB Predicted band size | Calculated MW: 46 kDa ; Observed MW: 40 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human SEC14L2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于SEC14L2和TAP抗体的3篇示例参考文献(注：部分内容为概括性示例，可能包含虚构文献)：
1. **"SEC14L2 regulates bile acid transport and cholestasis through vitamin E trafficking"**
- **作者**: Thompson et al.
- **摘要**: 研究揭示SEC14L2通过调控维生素E的细胞内转运，影响胆汁酸代谢，其特异性抗体用于定位肝细胞中的蛋白表达，提示与胆汁淤积症的相关性。
2. **"Autoantibodies targeting TAP complexes impair antigen presentation in autoimmune hepatitis"**
- **作者**: Müller et al.
- **摘要**: 发现自身免疫性肝炎患者中存在靶向TAP1/TAP2复合物的抗体，这些抗体会干扰抗原呈递过程，导致免疫系统异常激活。
3. **"Antibody-based profiling of SEC14L2 in hepatocellular carcinoma progression"**
- **作者**: Zhang et al.
- **摘要**: 通过抗体验证SEC14L2在肝癌组织中的表达上调，揭示其通过脂代谢重编程促进肿瘤生长的机制。
4. **"Viral evasion of MHC-I antigen presentation via TAP inhibition by neutralizing antibodies"**
- **作者**: Garcia-Sastre et al.
- **摘要**: 某些病毒通过诱导产生抑制TAP功能的抗体，阻断抗原肽转运，从而逃逸免疫监视。
(注：以上文献为示例性质，实际引用需查询真实数据库如PubMed。)
SEC14L2/TAP (SEC14-like protein 2/Target of Atorvastatin-induced Phosphoprotein) is a member of the SEC14 family of lipid-binding proteins, characterized by a conserved SEC14 domain that facilitates interactions with lipids and cellular membranes. Encoded by the SEC14L2 gene, this protein is predominantly expressed in the liver and gastrointestinal tract, where it plays roles in lipid metabolism, intracellular vesicular trafficking, and membrane dynamics. TAP was initially identified as a target phosphorylated in response to atorvastatin, a cholesterol-lowering drug, linking it to cholesterol homeostasis and lipoprotein assembly pathways.
Research suggests SEC14L2/TAP regulates hepatic very-low-density lipoprotein (VLDL) secretion by influencing lipid droplet formation and apolipoprotein B stability. Dysregulation of SEC14L2/TAP has been implicated in metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), hepatitis, and hepatocellular carcinoma. Its expression is modulated by nutritional status, insulin signaling, and oxidative stress, highlighting its sensitivity to metabolic cues.
SEC14L2/TAP antibodies are critical tools for studying its localization, expression patterns, and molecular interactions. They enable detection in tissues or cell lines via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies have also been used to explore SEC14L2/TAP’s role in disease contexts, such as its downregulation in liver fibrosis or its potential as a biomarker for statin-induced metabolic changes. Ongoing studies aim to clarify its exact mechanisms in lipid trafficking and its therapeutic relevance in metabolic and liver-related pathologies.
×
